​

Exact Sciences (EXAS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

EXAS Stock Forecast

Exact Sciences (EXAS) stock forecast, based on 36 Wall Street analysts, predicts a 12-month average price target of $71.40, with a high of $95.00 and a low of $60.00. This represents a 71.72% increase from the last price of $41.58.

$40 $51 $62 $73 $84 $95 High: $95 Avg: $71.4 Low: $60 Last Closed Price: $41.58

EXAS Stock Rating

Exact Sciences stock's rating consensus is Buy, based on 36 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 29 Buy (80.56%), 5 Hold (13.89%), 2 Sell (5.56%), and 0 Strong Sell (0.00%).

Buy
Total 36 2 5 29 0 Strong Sell Sell Hold Buy Strong Buy

EXAS Price Target Upside V Benchmarks

TypeNameUpside
StockExact Sciences71.72%
SectorHealthcare Stocks 35.25%
IndustryDiagnostics & Research Stocks46.62%

Price Target Trends

1M3M12M
# Anlaysts1115
Avg Price Target$60.00$60.00$75.93
Last Closing Price$41.58$41.58$41.58
Upside/Downside44.30%44.30%82.61%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 256173--26
Mar, 256172--25
Feb, 255173--25
Jan, 255173--25
Dec, 243173--23
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 28, 2025Subbu NambiGuggenheim$60.00$44.9933.36%44.30%
Jan 02, 2025Vijay KumarEvercore ISI$70.00$56.9322.96%68.35%
Nov 06, 2024Catherine SchulteRobert W. Baird$67.00$72.42-7.48%61.14%
Nov 06, 2024Mark MassaroBTIG$65.00$72.42-10.25%56.33%
Oct 29, 2024Kyle MiksonCanaccord Genuity$95.00$69.3536.99%128.48%
Oct 01, 2024Vijay KumarEvercore ISI$80.00$68.1217.44%92.40%
Sep 16, 2024Mark MassaroBTIG$82.00$69.4818.02%97.21%
Sep 16, 2024Patrick DonnellyCitigroup$80.00$67.9017.82%92.40%
Sep 13, 2024Kyle MiksonCanaccord Genuity$75.00$67.3911.29%80.38%
Sep 12, 2024David WestenbergPiper Sandler$85.00$66.9327.00%104.43%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 28, 2025GuggenheimBuyBuyhold
Jan 02, 2025Evercore ISIOutperformOutperformhold
Oct 29, 2024Wells FargoBuyBuyhold
Oct 29, 2024Canaccord GenuityBuyBuyhold
Oct 04, 2024Leerink PartnersOutperformOutperformhold
Oct 01, 2024Piper SandlerUnderperformUnderperformhold
Sep 16, 2024BTIGBuyBuyhold
Sep 16, 2024CitigroupBuyBuyhold
Sep 13, 2024Canaccord GenuityBuyBuyhold
Sep 12, 2024Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 $0 $1 $2 $3 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-5.61$-3.48$-3.54$-1.13$-5.59----
Avg Forecast$-2.98$-3.11$-3.63$-1.28$-1.16$-0.31$0.58$1.02$1.29
High Forecast$-2.94$-3.07$-3.55$-1.25$-1.10$0.10$1.48$2.01$1.33
Low Forecast$-3.05$-3.19$-3.70$-1.37$-1.23$-1.18$-0.70$-0.11$1.26
Surprise %88.26%11.90%-2.48%-11.72%381.90%----

Revenue Forecast

$1B $2B $2B $3B $4B $5B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.49B$1.77B$2.08B$2.50B$2.76B----
Avg Forecast$1.47B$1.74B$2.05B$2.49B$2.75B$3.06B$3.44B$3.79B$4.07B
High Forecast$1.50B$1.78B$2.09B$2.51B$2.76B$3.12B$3.44B$3.81B$4.17B
Low Forecast$1.45B$1.72B$2.02B$2.45B$2.74B$3.03B$3.44B$3.77B$4.00B
Surprise %1.59%1.38%1.48%0.37%0.44%----

Net Income Forecast

$-6B $-4B $-3B $-2B $-700M $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-848.53M$-595.63M$-623.51M$-204.15M$-1.03B----
Avg Forecast$-4.55B$-483.64M$-726.05M$-204.15M$-214.04M$-92.28M$66.66M$183.02M$232.39M
High Forecast$-3.64B$-386.91M$-580.84M$-163.32M$-198.19M$18.02M$266.73M$361.87M$239.16M
Low Forecast$-5.46B$-580.37M$-871.25M$-244.98M$-220.79M$-212.48M$-125.70M$-19.61M$226.88M
Surprise %-81.37%23.15%-14.12%-380.69%----

EXAS Forecast FAQ

Is Exact Sciences stock a buy?

Exact Sciences stock has a consensus rating of Buy, based on 36 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 29 Buy, 5 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Exact Sciences is a favorable investment for most analysts.

What is Exact Sciences's price target?

Exact Sciences's price target, set by 36 Wall Street analysts, averages $71.4 over the next 12 months. The price target range spans from $60 at the low end to $95 at the high end, suggesting a potential 71.72% change from the previous closing price of $41.58.

How does Exact Sciences stock forecast compare to its benchmarks?

Exact Sciences's stock forecast shows a 71.72% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the diagnostics & research stocks industry (46.62%).

What is the breakdown of analyst ratings for Exact Sciences over the past three months?

  • April 2025: 23.08% Strong Buy, 65.38% Buy, 11.54% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 24.00% Strong Buy, 68.00% Buy, 8.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 20.00% Strong Buy, 68.00% Buy, 12.00% Hold, 0% Sell, 0% Strong Sell.

What is Exact Sciences’s EPS forecast?

Exact Sciences's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.31, marking a -94.45% decrease from the reported $-5.59 in 2024. Estimates for the following years are $0.58 in 2026, $1.02 in 2027, and $1.29 in 2028.

What is Exact Sciences’s revenue forecast?

Exact Sciences's average annual revenue forecast for its fiscal year ending in December 2025 is $3.06B, reflecting a 10.77% increase from the reported $2.76B in 2024. The forecast for 2026 is $3.44B, followed by $3.79B for 2027, and $4.07B for 2028.

What is Exact Sciences’s net income forecast?

Exact Sciences's net income forecast for the fiscal year ending in December 2025 stands at $-92.282M, representing a -91.03% decrease from the reported $-1.029B in 2024. Projections indicate $66.66M in 2026, $183.02M in 2027, and $232.39M in 2028.